Drug profile · INN
atrasentan hydrochloride
VANRAFIA
atrasentan hydrochloride (VANRAFIA) is a endothelin receptor et-a antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — atrasentan hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
atrasentan hydrochloride (VANRAFIA) is a endothelin receptor et-a antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Endothelin receptor ET-A antagonist
Primary target: Endothelin-1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Congress & event coverage
- PresentationASCO 2026
Related & competitor drugs
Frequently asked questions
What is atrasentan hydrochloride?
atrasentan hydrochloride (VANRAFIA) is a endothelin receptor et-a antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for atrasentan hydrochloride?
VANRAFIA is a marketed brand name for atrasentan hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of atrasentan hydrochloride?
atrasentan hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.